Baxter acquires AesRx, specific terms not disclosed Baxter announced the acquisition of AesRx, including the development and commercialization of Aes-103. The Aes-103 program is currently in a Phase 2 clinical trial as part of an ongoing collaboration with the NIH’s National Center for Advancing Translational Sciences through its Therapeutics for Rare and Neglected Diseases program. Data has previously been presented from an escalating dose Phase I/2a safety study involving administration of a single dose among stable SCD patients. The compound was developed by a team from the VCU Institute for Structural Biology and Drug Discovery. Baxter made an initial payment to acquire the company and may make additional future payments based on specified development, regulatory and commercial milestones. The specific terms of the agreement were not disclosed.